Skip to content

Kankamol Jaisin

2 papers in the library · 11 citations · publishing 2024

Papers

Sort Most recent Most cited

A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

BMC Psychiatry July 18, 2024 Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. 11 citations

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management...

DOI: 10.1186/s12888-024-05951-5 (opens in new tab) Full text (opens in new tab) Response Tolerability Depression treatment Ketamine therapy +3

Intravenous ketamine is ineffective compared to midazolam for treatment-resistant depression: a double-blind, randomized controlled study

Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. preprint

Abstract Background: Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent...